MedGenome, a prominent genomic diagnostics company, has launched the Methylation Classifier Test (MCT) in India. This marks a significant milestone as it is the first such launch in the country, designed to enhance the precision of brain and central nervous system (CNS) tumor diagnosis. The advanced test helps differentiate and classify more than 90 types of CNS tumors, ultimately supporting doctors in making more accurate diagnoses and guiding targeted treatment decisions. [2]
The introduction of the Methylation Classifier Test occurred at a precision oncology symposium in Mumbai, co-hosted by MedGenome and Illumina. This event gathered leading oncologists, neuro-onco surgeons, pathologists, researchers, and doctoral students, underscoring the collaborative effort to advance neuro-oncology. [2]
Understanding the Methylation Classifier Test
The Methylation Classifier Test complements conventional histology by analyzing the tumor’s genome for specific molecular changes. These changes influence tumor behavior and treatment response. For instance, using advanced DNA methylation profiling, the test generates a unique molecular signature for each tumor. This signature is then compared against a comprehensive global reference database to accurately identify its subtype. [2, 3] This method proves particularly valuable for improving diagnostic precision. It helps especially in rare and challenging-to-classify cases, where traditional pathology alone might be insufficient. [2, 4, 5]
The test aligns with the World Health Organization’s (WHO) 2021 guidelines for CNS tumor classification. These guidelines place a greater emphasis on integrating molecular features, including DNA methylation patterns. This ensures more precise diagnosis and grading of CNS neoplasms. [1, 7, 8, 11] The WHO 2021 classification represents a significant shift. It moves beyond purely histological findings to incorporate genetic and epigenetic alterations for a comprehensive integrated diagnosis. [9, 11]
Benefits for Patients and Clinicians
Clinicians receive comprehensive results within 21 days. These reports include WHO grade assignment, genome-wide copy number profiling, and the detection of key gene alterations. Therefore, doctors gain a more complete understanding of the tumor’s biology, enabling more informed and personalized treatment planning. [2, 10] For example, accurate classification can significantly impact treatment strategies, leading to improved patient outcomes. [4, 6]
Methylation profiling identifies specific tumor subtypes, even in cases previously labeled “not otherwise specified”. This streamlines the diagnostic pathway. It reduces diagnostic errors and helps avoid inconclusive diagnoses, ensuring patients receive appropriate care faster. [10, 13] Consequently, this innovation in molecular diagnostics represents a substantial step forward for neuro-oncology in India. [12]
Frequently Asked Questions
Q1: What is the Methylation Classifier Test?
The Methylation Classifier Test (MCT) is an advanced diagnostic tool launched by MedGenome in India. It differentiates and classifies over 90 types of brain and central nervous system (CNS) tumors by analyzing DNA methylation patterns, creating a unique molecular signature matched against a global database for precise subtyping. [2, 3]
Q2: How does the Methylation Classifier Test improve tumor diagnosis?
This test enhances diagnostic accuracy by identifying molecular changes that influence tumor behavior and treatment response, complementing traditional histology. It is especially useful for rare or difficult-to-classify cases, aligning with the WHO 2021 guidelines that emphasize molecular insights for classification. [2, 11]
Q3: What information do clinicians receive from the test results?
Within 21 days, clinicians receive detailed results including WHO grade assignment, genome-wide copy number profiling, and the detection of key gene alterations. This comprehensive data provides a deeper understanding of the tumor’s biology, supporting targeted treatment decisions. [2]
References
- MedGenome Launches CNS Tumor Methylation Classifier Test in India – ETHealthworld
- The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview – PMC
- India’s 1st CNS Tumor Methylation Classifier – MedGenome
- (PDF) The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care – ResearchGate
- Diagnosing Central Nervous System Tumors More Precisely with Methylation Marks – NCI
- Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics | Neuro-Oncology | Oxford Academic
- The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know | American Journal of Neuroradiology
- 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist – UCL Discovery
- The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas – MDPI
- (PDF) Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing – ResearchGate
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary – PMC
- MedGenome’s CNS Tumor Classifier – A Breakthrough in Brain Tumor Diagnostics – YouTube
- Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact – PubMed Central
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.